Development of Prednisone: Polyethylene Glycol 6000 Fast-Release Tablets From Solid Dispersions: Solid-State Characterization, Dissolution Behavior, and Formulation Parameters

被引:50
作者
Leonardi, Dario [1 ]
Gabriela Barrera, Maria [1 ]
Celina Lamas, Maria [1 ]
Javier Salomon, Claudio [1 ,2 ]
机构
[1] Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Farm, CONICET,IQUIOS, RA-2000 Rosario, Santa Fe, Argentina
[2] Consejo Nacl Invest Cient & Tecn, Inst Quim Organ Sintesis, RA-2000 Rosario, Santa Fe, Argentina
关键词
Solid dispersions; PEG; 6000; prednisone; dissolution rate; tablets;
D O I
10.1208/pt0804108
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the current study was to design oral fast-release polymeric tablets of prednisone and to optimize the drug dissolution profile by modifying the carrier concentration. Solid dispersions were prepared by the solvent evaporation method at different drug: polymer ratios (wt/wt). The physical state and drug: carrier interactions were analyzed by X-ray diffraction, infrared spectroscopy, and scanning electron microscopy. The dissolution rate of prednisone from solid dispersions was markedly enhanced by increasing the polymer concentration. The tablets were prepared from solid dispersion systems using polyethylene glycol (PEG) 6000 as a carrier at low and high concentration. The results showed that PEG 6000-based tablets exhibited a significantly higher prednisone dissolution (80% within 30 minutes) than did conventional tablets prepared without PEG 6000 (< 25% within 30 minutes). In addition, the good disintegration and very good dissolution performance of the developed tablets without the addition of superdisintegrant highlighted the suitability of these formulated dosage forms. The stability studies performed in normal and accelerated conditions during 12 months showed that prednisone exhibited high stability in PEG 6000 solid dispersion powders and tablets. The X-ray diffraction showed that the degree of crystallinity of prednisone in solid dispersions decreased when the ratio of the polymer increased, suggesting that the drug is present inside the samples in different physical states. The Fourier transform infrared spectroscopic studies showed the stability of prednisone and the absence of well-defined drug: polymer interactions. Scanning electron microscopy images showed a novel morphology of the dispersed systems in comparison with the pure components.
引用
收藏
页数:8
相关论文
共 36 条
[1]   Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers [J].
Ahuja, Naveen ;
Katare, Om Prakash ;
Singh, Bhupinder .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 65 (01) :26-38
[2]   DISSOLUTION RATES OF HYDROCORTISONE AND PREDNISONE UTILIZING SUGAR SOLID DISPERSION SYSTEMS IN TABLET FORM [J].
ALLEN, LV ;
LEVINSON, RS ;
DEMARTONO, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1978, 67 (07) :979-981
[3]   DISSOLUTION RATES OF CORTICOSTEROIDS UTILIZING SUGAR GLASS DISPERSIONS [J].
ALLEN, LV ;
YANCHICK, VA ;
MANESS, DD .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1977, 66 (04) :494-497
[4]   ENHANCEMENT OF DISSOLUTION RATES OF POORLY WATER-SOLUBLE DRUGS BY CRYSTALLIZATION IN AQUEOUS SURFACTANT SOLUTIONS .1. SULFATHIAZOLE, PREDNISONE, AND CHLORAMPHENICOL [J].
CHIOU, WL ;
CHEN, SJ ;
ATHANIKAR, N .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1976, 65 (11) :1702-1704
[5]   Formulation and production of rapidly disintegrating tablets by lyophilisation using hydrochlorothiazide as a model drug [J].
Corveleyn, S ;
Remon, JP .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 152 (02) :215-225
[6]   CORTICOSTEROIDS AND INFECTIOUS DISEASES [J].
DALE, DC ;
PETERSDO.RG .
MEDICAL CLINICS OF NORTH AMERICA, 1973, 57 (05) :1277-1287
[7]  
Dastmalchi S, 2005, J PHARM PHARM SCI, V8, P175
[8]  
Ferrari F, 1996, Pharm Dev Technol, V1, P159, DOI 10.3109/10837459609029890
[9]   Diclofenac salts, II.: Solid dispersions in PEG6000 and Gelucire 50/13 [J].
Fini, A ;
Moyano, JR ;
Ginés, JM ;
Perez-Martinez, JI ;
Rabasco, AM .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2005, 60 (01) :99-111
[10]   CLINICAL PHARMACOKINETICS OF PREDNISONE AND PREDNISOLONE [J].
FREY, BM ;
FREY, FJ .
CLINICAL PHARMACOKINETICS, 1990, 19 (02) :126-146